Cagrilintide, CagriSema, and semaglutide
These names can blur together in a search. Keeping them apart helps you check what studies found and which medicine is approved.
Facts checked September 28, 2026.
CagriSema joins different drugs
CagriSema combines cagrilintide with semaglutide.
Semaglutide is a different medicine that copies a body message affecting hunger and blood sugar.
The combination was still being studied and had no FDA approval as of September 28, 2026.
A result for the combination cannot be credited to cagrilintide alone.
Semaglutide has its own story
Semaglutide (Ozempic, Wegovy, Rybelsus) is a different drug.
The body message it copies is a gut hormone: a chemical message released after food.
At the September 26, 2026 check, Wegovy had FDA approval for weight treatment; the FDA is the US drug regulator.
For adults with type 2 diabetes, Ozempic shots have approval to help control blood sugar.
For adults who also have heart disease, they are approved to reduce the risk of heart attack and stroke.
For adults with type 2 diabetes and long-term kidney disease, they are approved to slow kidney disease and reduce the risk of death from heart disease.
Ozempic is not approved for weight loss.
Get the medicine’s name, then ask which form it comes in: pill or shot. Ask to see the label, meaning the official medicine information.
The approval does not travel across
Semaglutide’s approval does not make the CagriSema combination approved; as of September 28, 2026, that combination still has no FDA approval.
A mix of medicines offered online may not match the medicine used in CagriSema studies.
Ask for the full drug name rather than accepting a nickname.
